Algernon Pharmaceuticals completed its clinical trial agreement with Westchester Research Center at Westchester General Hospital in Miami, Florida, for its multinational Phase IIb/III trial of NP-120 (ifenprodil) for COVID-19. The trial is expected to start after July 20.
The meeting date assigned by the FDA is June 9, 2024
TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research a
Using the platform powered by advanced AI algorithms, Rakovina can quickly analyze billions of molecular structures ..
© 2023 Frontier Merchant Capital Group. All Rights Reserved.